Skip to content

Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults

Open-label Randomized Controlled Trial Investigating the Effects of Peanut Protein Powder Supplement on Muscle Growth, Muscle Quality and Other Health Biomarkers in Older Adults Engaging in a Ten-week, Whole-body Resistance Training Program

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04015479
Enrollment
41
Registered
2019-07-11
Start date
2019-09-26
Completion date
2020-05-01
Last updated
2021-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Sarcopenia

Keywords

muscle protein synthesis, resistance training, protein supplementation, skeletal muscle physiology, inflammatory cytokines, fecal microbiome, plant protein

Brief summary

This study will evaluate the adaptations in skeletal muscle that occur in response to 10 weeks of weight training with or without peanut protein supplementation in older adult men and women.

Detailed description

Aging is associated with declines in muscle mass, physical strength and physical function. Adequate quality protein intake in aging adults is critical to preventing functional decline. Peanuts provide a unique blend of amino acids that can provide several health benefits to aging adults. While supplementing with peanut protein (PP) powder as part of a resistance training program may increase myofibrillar protein synthesis (i.e., the gold standard molecular assessment in deciphering a muscle-building response), and improve skeletal muscle quality and body composition, no study to date has made this determination. This is a two-phase study using both novel and conventional methods to assess how PP supplementation affects muscle tissue in older individuals who engage in resistance training. These two phases will be conducted as part of a 10-week randomized controlled trial in which men and women aged 50 years and older (n=60), will be stratified by gender and randomized to a resistance training intervention (whole body, two days per week) with PP powder (72g daily; n=15 males, n=15 females) provided during the intervention (immediate group, IG) or after the intervention (wait-list control, WLC, n=15 males, n=15 females). The aims of this study are to determine the acute (deuterium oxide tracer) and chronic (peripheral quantitative computed tomography) effects of PP during resistance training on skeletal muscle myofibrillar protein synthesis rates, changes in skeletal muscle size and quality, changes in whole and appendicular body composition (dual energy x-ray absorptiometry), changes in inflammatory markers and the fecal microbiome.

Interventions

DIETARY_SUPPLEMENTPeanut Protein Powder

Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water

Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)

Sponsors

Edward Via Virginia College of Osteopathic Medicine
CollaboratorOTHER
The Peanut Institute
CollaboratorOTHER
Auburn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

PI and Co-Is will be blind to participant randomization. One study staff member will be responsible for administering the supplements to participants per randomization

Intervention model description

Intervention group will receive the supplement during the study period and the wait-listed control group will receive the supplement after the study period. Both groups will participate in resistance training during the 10 week period

Eligibility

Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* body mass index (body mass/height squared) less than 35 kg/m2 * resting blood pressure averaging less than 140/90 mmHg (with or without medication)

Exclusion criteria

* known peanut allergy * actively participating in resistance training for more than 2 days/week * any known overt cardiovascular or metabolic disease * metal implants that will interfere with x-ray procedures * medically necessary radiation exposure in the last six months (except dental x-ray) * any medical condition that would contradict participating in an exercise program, giving blood or donating a skeletal muscle biopsy (i.e. blood clotting disorder or taking blood thinners)

Design outcomes

Primary

MeasureTime frameDescription
Change in acute myofibrillar protein synthesis rates24 hoursChange in right leg vastus lateralis myofibrillar protein synthesis rates using the integrated deuterium oxide technique from biopsies immediately before and 24 hours after resistance exercise
Change in mid-thigh skeletal muscle area and quality0-10 weeksperipheral quantitative computed tomography (pQCT) cross-sectional image of mid-right thigh assessed for total muscle cross-sectional area, subcutaneous adipose tissue area, total intra- and inter-muscular adipose tissue area and overall muscle density

Secondary

MeasureTime frameDescription
Change in leg extensor isokinetic dynamometry0-10 weeksmaximal isokinetic right leg extensions on an isokinetic dynamometer (BioDex)
Change in whole-body and appendicular body composition0-10 weeksdual energy x-ray absorptiometry (DXA)
Change in fecal microbiome composition0-10 weeksalpha- and beta-diversity of 16S bacterial rDNA
Change in inflammatory biomarkers0-10 weeksserum C-reactive protein, interleukin-6, tumor necrosis factor-alpha, plasma 8-hydroxy-2'deoxyguanosine
Change in Type I and II Muscle Fiber Cross-Sectional Area0-10 weeksMuscle biopsy immunofluorescent staining for determination of type I and type II muscle fiber cross sectional area (fCSA) as a cellular determinant of skeletal muscle hypertrophy

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026